Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus

被引:20
作者
Lerang, Karoline [1 ,2 ]
Gilboe, Inge-Margrethe [1 ]
Gran, Jan Tore [1 ,3 ]
机构
[1] Oslo Univ Hosp, Rikshosp, Dept Rheumatol, N-0424 Oslo, Norway
[2] Univ Oslo, Norwegian Resource Ctr Womens Hlth, Oslo, Norway
[3] Univ Oslo, Inst Clin Med, Oslo, Norway
关键词
systemic lupus erythematosus; physician's practice patterns; prescription pattern; hydroxychloroquine; anti-phospholipid antibody; RHEUMATOID-ARTHRITIS; REVISED CRITERIA; CLASSIFICATION; COHORT; HYDROXYCHLOROQUINE; RECOMMENDATIONS; MANAGEMENT;
D O I
10.1093/rheumatology/ker318
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To compare the diagnostics and treatment of SLE patients in the care of rheumatologists with patients in the care of other specialities within a geographically complete cohort. Methods. Nine different sources were used to identify SLE patients resident in Oslo between 1999 and 2008. Only SLE patients fulfilling four or more of the updated 1997 ACR criteria were included. Data were extracted from medical records. The patients were classified into three groups according to each patient's responsible doctor's speciality. Results. A total of 325 SLE patients were included in the study. Of these, 227 had solely been in the care of rheumatologists (rheumatology group), 34 had solely been in the care of nephrologists, haematologists or infectious disease specialists (non-rheumatology group) and 64 had been in the care of both rheumatologists and other specialists (multidisciplinary group). Even though patients in the non-rheumatology group and multidisciplinary group showed similar disease characteristics, patients in the non-rheumatology group were less often tested for aPLs (68 vs 94%; P = 0.001) and less often treated with HCQ (12 vs 78%; P < 0.001). Conclusions. In contrast to rheumatologists, non-rheumatologists do not routinely test all SLE patients for aPLs, and rarely prescribe HCQ. These findings indicate that more communication between different specialists caring for SLE is needed, and highlights an area in need of agreement.
引用
收藏
页码:663 / 669
页数:7
相关论文
共 30 条
[11]   International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J].
Miyakis, S ;
Lockshin, MD ;
Atsumi, T ;
Branch, DW ;
Brey, RL ;
Cervera, R ;
Derksen, RHWM ;
De Groot, PG ;
Koike, T ;
Meroni, PL ;
Reber, G ;
Shoenfeld, Y ;
Tincani, A ;
Vlachoyiannopoulos, PG ;
Krilis, SA .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :295-306
[12]  
Molina Maria J, 2008, Ethn Dis, V18, pS2
[13]   Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis [J].
Moroni, G ;
Ventura, D ;
Riva, P ;
Panzeri, P ;
Quaglini, S ;
Banfi, G ;
Simonini, P ;
Bader, R ;
Meroni, PL ;
Ponticelli, C .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (01) :28-36
[14]   Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice [J].
Mosca, M. ;
Tani, C. ;
Aringer, M. ;
Bombardieri, S. ;
Boumpas, D. ;
Cervera, R. ;
Doria, A. ;
Jayne, D. ;
Khamashta, M. A. ;
Kuhn, A. ;
Gordon, C. ;
Petri, M. ;
Schneider, M. ;
Shoenfeld, Y. ;
Smolen, J. S. ;
Talarico, R. ;
Tincani, A. ;
Ward, M. M. ;
Werth, V. P. ;
Carmona, L. .
AUTOIMMUNITY REVIEWS, 2011, 10 (07) :383-388
[15]   European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies [J].
Mosca, M. ;
Tani, C. ;
Aringer, M. ;
Bombardieri, S. ;
Boumpas, D. ;
Brey, R. ;
Cervera, R. ;
Doria, A. ;
Jayne, D. ;
Khamashta, M. A. ;
Kuhn, A. ;
Gordon, C. ;
Petri, M. ;
Rekvig, O. P. ;
Schneider, M. ;
Sherer, Y. ;
Shoenfeld, Y. ;
Smolen, J. S. ;
Talarico, R. ;
Tincani, A. ;
van Vollenhoven, R. F. ;
Ward, M. M. ;
Werth, V. P. ;
Carmona, L. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (07) :1269-1274
[16]   Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study [J].
Norby, Gudrun E. ;
Strom, Erik H. ;
Midtvedt, Karsten ;
Hartmann, Anders ;
Gilboe, Inge-Margrethe ;
Leivestad, Torbjorn ;
Stenstrom, Jean ;
Holdaas, Hallvard .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (08) :1484-1487
[17]  
Norby Gudrun E, 2010, Tidsskr Nor Laegeforen, V130, P1140, DOI 10.4045/tidsskr.09.0583
[18]   Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus [J].
Nossent, J. ;
Kiss, E. ;
Rozman, B. ;
Pokorny, G. ;
Vlachoyiannopoulos, P. ;
Olesinska, M. ;
Marchesoni, A. ;
Mosca, M. ;
Pai, S. ;
Manger, K. ;
Schneider, M. ;
Nielsen, H. ;
van Vollenhoven, R. ;
Swaak, T. .
LUPUS, 2010, 19 (08) :949-956
[19]   Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice [J].
Roubey, R. A. S. .
LUPUS, 2010, 19 (04) :440-445
[20]   Hydroxychloroquine: the cornerstone of lupus therapy [J].
Ruiz-Irastorza, G. ;
Khamashta, M. A. .
LUPUS, 2008, 17 (04) :271-273